Regeneron Pharmaceuticals Inc. (REGN): Price and Financial Metrics


Regeneron Pharmaceuticals Inc. (REGN): $783.13

31.93 (+4.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add REGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

REGN POWR Grades

  • Quality is the dimension where REGN ranks best; there it ranks ahead of 86.92% of US stocks.
  • The strongest trend for REGN is in Quality, which has been heading down over the past 177 days.
  • REGN ranks lowest in Growth; there it ranks in the 1st percentile.

REGN Stock Summary

  • REGN has a higher market value than 97.36% of US stocks; more precisely, its current market capitalization is $81,807,133,572.
  • REGENERON PHARMACEUTICALS INC's stock had its IPO on April 2, 1991, making it an older stock than 85.39% of US equities in our set.
  • Of note is the ratio of REGENERON PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; just 17.8% of US stocks have a lower such ratio.
  • Stocks with similar financial metrics, market capitalization, and price volatility to REGENERON PHARMACEUTICALS INC are LRCX, AMAT, VRTX, CDNS, and SNPS.
  • REGN's SEC filings can be seen here. And to visit REGENERON PHARMACEUTICALS INC's official web site, go to www.regeneron.com.

REGN Valuation Summary

  • REGN's EV/EBIT ratio is 13; this is 28.08% higher than that of the median Healthcare stock.
  • REGN's EV/EBIT ratio has moved up 21.9 over the prior 243 months.

Below are key valuation metrics over time for REGN.

Stock Date P/S P/B P/E EV/EBIT
REGN 2023-01-30 5.8 3.7 14.9 13.0
REGN 2023-01-27 5.9 3.8 15.1 13.1
REGN 2023-01-26 5.9 3.8 15.1 13.1
REGN 2023-01-25 5.9 3.8 15.0 13.1
REGN 2023-01-24 5.8 3.7 14.8 12.9
REGN 2023-01-23 5.8 3.7 14.8 12.9

REGN Growth Metrics

    The 5 year revenue growth rate now stands at 60.28%.
  • Its 3 year price growth rate is now at 104.98%.
  • The 3 year revenue growth rate now stands at 138.86%.
Over the past 33 months, REGN's revenue has gone up $5,846,800,000.

The table below shows REGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 13,710.2 5,667.5 5,370.3
2022-06-30 14,226.8 8,452.2 5,686.8
2022-03-31 16,508.1 8,514.5 7,933.6
2021-12-31 16,071.7 7,081.3 8,075.3
2021-09-30 13,542.9 5,939.8 6,995.5
2021-06-30 12,384.1 2,271.9 6,205.4

REGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • REGN has a Quality Grade of B, ranking ahead of 86.94% of graded US stocks.
  • REGN's asset turnover comes in at 0.683 -- ranking 43rd of 681 Pharmaceutical Products stocks.
  • JAZZ, AGLE, and VERU are the stocks whose asset turnover ratios are most correlated with REGN.

The table below shows REGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.683 0.868 0.456
2021-03-31 0.562 0.868 0.315
2020-12-31 0.536 0.868 0.292
2020-09-30 0.540 0.880 0.283
2020-06-30 0.543 0.882 0.282
2020-03-31 0.553 0.897 0.221

REGN Price Target

For more insight on analysts targets of REGN, see our REGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $683.25 Average Broker Recommendation 1.52 (Moderate Buy)

REGN Stock Price Chart Interactive Chart >

Price chart for REGN

REGN Price/Volume Stats

Current price $783.13 52-week high $789.95
Prev. close $751.20 52-week low $538.01
Day low $758.63 Volume 1,448,500
Day high $789.95 Avg. volume 678,448
50-day MA $735.37 Dividend yield N/A
200-day MA $676.33 Market Cap 85.28B

Regeneron Pharmaceuticals Inc. (REGN) Company Bio


Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester CountyNew York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors. (Wikipedia:Source)


REGN Latest News Stream


Event/Time News Detail
Loading, please wait...

REGN Latest Social Stream


Loading social stream, please wait...

View Full REGN Social Stream

Latest REGN News From Around the Web

Below are the latest news stories about REGENERON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate REGN as an investment opportunity.

Drug, Chip Stocks Hit 52-Week Highs As One Breaks Out Of Bullish Chart Pattern

Regeneron and Analog Devices hit new highs and break out. REGN had strong fourth quarter earnings. ADI is leader in the chip industry

Yahoo | February 3, 2023

Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples

Regeneron Pharma beat quarterly forecasts Friday, but its partner Sanofi posted a mixed report. Regeneron stock rose as SNY stock toppled.

Yahoo | February 3, 2023

Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Yahoo | February 3, 2023

Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline

Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.

Yahoo | February 3, 2023

Regeneron’s Earnings Beat Forecasts, With No Sales of Covid-19 Treatment

The pharmaceuticals company's total revenue dropped by 31% to $3.41 billion but beat the FactSet consensus of $3.13 billion.

Yahoo | February 3, 2023

Read More 'REGN' Stories Here

REGN Price Returns

1-mo 6.24%
3-mo 4.29%
6-mo 25.87%
1-year 25.71%
3-year 100.88%
5-year 131.15%
YTD 8.54%
2022 14.25%
2021 30.72%
2020 28.66%
2019 0.53%
2018 -0.65%

Continue Researching REGN

Want to see what other sources are saying about Regeneron Pharmaceuticals Inc's financials and stock price? Try the links below:

Regeneron Pharmaceuticals Inc (REGN) Stock Price | Nasdaq
Regeneron Pharmaceuticals Inc (REGN) Stock Quote, History and News - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6851 seconds.